Skip to content
MedsAcross

Molecule

Fluocinolone acetonide

Corticosteroid
Available on requestOrphanCardiologyOphthalmologyDermatology
Presentations
18
Brands
7
Manufacturers
5
Available from stock
0

Fluocinolone acetonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It is available as oil, topical solution and cream for otic and intravitreal use. MedsAcross supplies Fluocinolone acetonide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Corticosteroid, Corticosteroid Hormone Receptor Agonists
ATC classification
C05AA10 Fluocinolone acetonide · Vein and capillary protectors, subgroup C05A, subgroup C05AAD07AC04 Fluocinolone acetonide · Corticosteroids for the skin, subgroup D07A, subgroup D07ACS01BA15 Fluocinolone acetonide · Eye medicines, subgroup S01B, subgroup S01BAS02BA08 Fluocinolone acetonide · Corticosteroid
US FDA first approval
15 February 1963
EU status
Application withdrawn
Orphan designation
Yes
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Topical, Otic, Intravitreal
Dosage forms
Oil, Topical solution, Cream, Ointment, Implant
Identifiers
UNII 0CD5FD6S2MRxCUI 4461CAS 67-73-2DrugBank DB00591Q924467

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Fluocinolone Acetonide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Source: US FDA prescribing information

Dosing overview

Fluocinolone Acetonide Cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exercised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation. If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Source: US FDA prescribing information

Contraindications

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Source: US FDA prescribing information

Warnings and precautions

General Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Source: US FDA prescribing information

Side effects

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria or www.fda/gov/medwatch.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

18 presentations of Fluocinolone acetonide, sorted by availability.

MedicineManufacturerRegisterAvailability
Fluocinolone acetonide 0.1 mg/mL topical solutionTopicalGeneric name—US FDAAvailable on request
Fluocinolone acetonide 0.01 mg/100 mL oilTopicalGeneric name—US FDAAvailable on request
Fluocinolone acetonide 0.025% ointmentTopicalGeneric name—US FDAAvailable on request
Fluocinolone acetonide 0.11 mg/mL oilTopicalGeneric name—US FDAAvailable on request
Fluocinolone acetonide 0.11 mg/mL oilOticGeneric name—US FDAAvailable on request
Fluocinolone acetonide 0.01% creamTopicalGeneric name—US FDAAvailable on request
Fluocinolone acetonide 0.025% creamTopicalGeneric name—US FDAAvailable on request
Fluocinolone acetonide 0.11 mg/118.28 mL oilTopicalGeneric name—US FDAAvailable on request
FLUOCINOLONE ACETONIDE Oil 0.11 mg/mL oilTopicalRising Pharma HoldingsUS FDAAvailable on request
Derma-Smoothe/FS 0.11 mg/mL oilTopicalRoyal PharmaceuticalsUS FDAAvailable on request
Synalar 0.025% ointmentTopicalMedimetriks PharmaceuticalsUS FDAAvailable on request
Dermotic 0.11 mg/mL oilOticRoyal PharmaceuticalsUS FDAAvailable on request
Flac Otic Oil 0.11 mg/mL oilOticPatrin PharmaUS FDAAvailable on request
Fluocinolone Acetonide Oil 0.11 mg/mL oilTopicalRising Pharma HoldingsUS FDAAvailable on request
Fluocinolone Acetonide Oil 0.11 mg/mL oilOticRising Pharma HoldingsUS FDAAvailable on request
Iluvien 0.19 mg implantIntravitrealANI PharmaceuticalsUS FDAAvailable on request
Synalar 0.025% creamTopicalMedimetriks PharmaceuticalsUS FDAAvailable on request
Yutiq 0.18 mg implantIntravitrealANI PharmaceuticalsUS FDAAvailable on request

Brands by market

7 brand names across 1 markets.

Brand names by country

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 15 February 1963Drugs@FDA
EU (EMA)Application withdrawnEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenWithdrawnEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Questions and answers

Is Fluocinolone acetonide available for export from India?

Yes, on request. MedsAcross lists 18 presentations of Fluocinolone acetonide and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Fluocinolone acetonide have?

The catalogue lists 8 brand names for Fluocinolone acetonide, including Derma-Smoothe/FS, Dermotic, Flac Otic Oil, Fluocinolone Acetonide Oil, FLUOCINOLONE ACETONIDE Oil, Iluvien, Synalar, Yutiq.

Is Fluocinolone acetonide approved by the US FDA?

Yes. The US FDA first approved Fluocinolone acetonide on 15 February 1963, according to Drugs@FDA.

Does Fluocinolone acetonide need cold chain shipping?

No listed presentation of Fluocinolone acetonide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Fluocinolone acetonide in?

Fluocinolone acetonide is classified under ATC code C05AA10 (Fluocinolone acetonide).

References

  1. fluocinolone acetonide prescribing information (ANI Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 23 February 2026

Request Fluocinolone acetonide for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.